UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 21, 2006 (December 18, 2006)
Introgen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-21291
|
|
74-2704230 |
(State or other
jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
301 Congress Avenue, Suite 1850
Austin, Texas 78701
(Address of principal executive offices, including zip code)
(512) 708-9310
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On December 18, 2006, Introgen Therapeutics, Inc. (the “Company”) entered into an amendment to
its patent and technology license agreement dated July 20, 1994, with The University of Texas M. D.
Anderson Cancer Center and the Board of Regents of The University of Texas System (the “Board of
Regents”), which amendment is effective as of December 13, 2006. In connection with this
amendment, the Company obtained from the Board of Regents a worldwide, exclusive license to a
portfolio of patent applications directed at methods and compositions of use for INGN 241 in
combination with several currently available therapies, including conventional chemotherapies,
vascular endothelial growth factor inhibitors such as Avastin®, non-steroidal
anti-inflammatory drugs, including COX-2 inhibitors such as Celebrex®, and proteasome
inhibitors such as Velcade®.
Item 8.01. Other Events.
On December 21, 2006, the Company issued a press release announcing that it had obtained the
exclusive license to the portfolio of patent applications discussed above. A copy of the press release is
being filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
| |
99.1
|
|
Press Release dated December 21, 2006. |